

Visit <http://www.tinyurl.com/EyeOnCataract-6> for online testing and instant CME certificate.

Cataract Case of the Month CME Series

EYE ON CATARACT™

CHALLENGING CASES MADE ROUTINE

This Month's Case

Cataract Surgery in a Patient
With Keratoconus

ORIGINAL RELEASE: JUNE 1, 2016 • LAST REVIEW: APRIL 22, 2016 • EXPIRATION: JUNE 30, 2017

Program Chair

John Sheppard, MD, MMSc

Professor of Ophthalmology
Eastern Virginia Medical School
President
Virginia Eye Consultants
Norfolk, Virginia

Faculty

Anthony J. Aldave, MD

Associate Professor of Ophthalmology
The Jules Stein Eye Institute
University of California, Los Angeles
Los Angeles, California

Deepinder K. Dhaliwal, MD, LAc

Professor of Ophthalmology
Director, Cornea, Cataract, and External Disease Service
Director, Refractive and Laser Surgery Center
Director, UPMC Eye Center Monroeville
Director and Founder, Center of Integrative Eye Care
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Bonnie An Henderson, MD

Clinical Professor of Ophthalmology
Tufts University School of Medicine
Ophthalmic Consultants of Boston
Boston, Massachusetts

Jay S. Pepose, MD, PhD

Professor of Clinical Ophthalmology
Barnes-Jewish Hospital
Washington University School of Medicine
Medical Director
Pepose Vision Institute
St. Louis, Missouri

William B. Trattler, MD

Volunteer Assistant Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami
Director of Cornea
Center for Excellence in Eye Care
Miami, Florida

CME Reviewer for New York Eye and Ear Infirmary of Mount Sinai

Joseph F. Panarelli, MD

Assistant Professor of Ophthalmology
Icahn School of Medicine at Mount Sinai
Associate Residency Program Director
New York Eye and Ear Infirmary of Mount Sinai
New York, New York

LEARNING METHOD AND MEDIUM

This educational activity consists of a case discussion and study questions. The participant should, in order, read the learning objectives at the beginning of this case discussion, read the case discussion, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please visit <http://www.tinyurl.com/EyeOnCataract-6> and follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 0.75 hour to complete.

CONTENT SOURCE

This continuing medical education (CME) activity captures content from an expert roundtable discussion held in San Diego, California, on April 16, 2015.

ACTIVITY DESCRIPTION

Cataract surgery is the most commonly performed surgery among adults in the United States, and the number of patients undergoing this procedure is continuing to increase. For patients who are identified as candidates for cataract surgery, optimization of the ocular surface is critical for obtaining optimal patient outcomes. A host of new tools can help cataract surgeons with their preoperative evaluations. Among these are several tests that are useful adjuncts for diagnosing dry eye/meibomian gland dysfunction. The purpose of this activity is to update ophthalmologists on recent advances in the care of patients with cataracts.

TARGET AUDIENCE

This activity is intended for ophthalmologists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be better able to:

- Manage preoperative ocular surface conditions, with the potential to affect surgical outcomes in patients with cataracts
- Demonstrate optimal IOL selection, knowledge of appropriate refractive targets, and understanding of strategies for achieving intended goals
- Discuss the risks and benefits of cataract surgery with patients
- Describe the benefits of new diagnostic and surgical technologies with application to cataract surgery

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. The New York Eye and Ear Infirmary of Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai "Accreditation with Commendation," for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA CREDIT DESIGNATION STATEMENT

The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GRANTOR STATEMENT

This continuing medical education activity is supported through an unrestricted educational grant from Bausch + Lomb Incorporated.

DISCLOSURE POLICY STATEMENT

It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). New York Eye and Ear Infirmary of Mount Sinai has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

DISCLOSURES

Faculty had financial agreements or affiliations during the past year with commercial interests as follows:

Dr Aldave: Consultant/Advisory Board: Allergan; Nicox; and TearScience; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon; and Allergan; Other/Travel Support: Laboratoires Théa; and Tissue Banks International. **Dr Dhaliwal:** Consultant/Advisory Board: AMO Lasers; and NovaBay Pharmaceuticals; Research Grants: Abbott Medical Optics; Avedro; and Eleven Biotherapeutics. **Dr Henderson:** Consultant/Advisory Board: Abbott Medical Optics; Alcon; and Bausch + Lomb. **Dr Pepose:** Consultant/Advisory Board: Abbott Medical Optics; Alcon; Allergan; Bausch + Lomb; Shire; and TearLab; Ownership Interest: AcuFocus. **Dr Sheppard:** Consultant/Advisory Board: AbbVie; Alcon; Allergan; Bausch + Lomb;

Bio-Tissue; Omeros; TearLab; and TearScience; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon; Bausch + Lomb; ScienceBased Health; and TearLab; Ownership Interest: Alphaeon; EyeGate Pharma; OcuHub; Rapid Pathogen Screening; TearLab; and 1-800-Doctors. **Dr Trattler:** Consultant/Advisory Board: Abbott Medical Optics; Alcon; Allergan; and Bausch + Lomb; Contracted Research: Refocus Group; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; and OCULUS, Inc; Ownership Interest: Calhoun Vision; CXL Ophthalmics; and Rapid Pathogen Screening.

NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE

Joseph F. Panarelli, MD, has no relevant commercial relationships to disclose.

EDITORIAL SUPPORT DISCLOSURES

Cheryl Guttman (writer); Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubei; Diane McArdle, PhD; and Michelle Ong have no relevant commercial relationships to disclose.

DISCLOSURE ATTESTATION

The contributing individuals listed above have attested to the following:

- 1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- 2) that practice recommendations given relevant to the companies to whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- 3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

OFF-LABEL DISCUSSION

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

FOR DIGITAL EDITIONS

System Requirements:

To view this online activity, please ensure the computer you are using meets the following requirements:

- Operating System: Windows or Macintosh
- Media Viewing Requirements: Flash Player or Adobe Reader
- Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- A good Internet connection

New York Eye and Ear Infirmary of Mount Sinai

Privacy & Confidentiality Policies

<http://www.nyee.edu/health-professionals/cme/enduring-activities>

CME Provider Contact Information

For questions about this activity, call 212-979-4383.

TO OBTAIN AMA PRA CATEGORY 1 CREDIT™ for this activity, read the material in its entirety and consult referenced sources as necessary. We offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to <http://www.tinyurl.com/EyeOnCataract-6>. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

There are no fees for participating in and receiving CME credit for this activity.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Bausch + Lomb Incorporated, or *Ophthalmology Times*.

Jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC



MedEdicus

This CME activity is copyrighted to MedEdicus LLC ©2016. All rights reserved.



corneal higher-order aberration OS than OD (0.878 μm vs 0.299 μm) and particularly higher total coma OS than OD (0.790 μm vs 0.017 μm).

Astigmatism measurements obtained with 4 different methods (manual keratometry, automated keratometry, topography, and OLCR) are fairly consistent in the right eye for magnitude (range, 2.57-3.5 D) and axis (117°-123°), but the range of magnitude values is wider in the left eye (7.5-9.26 D).

Intraocular lens (IOL) calculations (Figure 3) performed using the OLCR IOL calculator with a target refraction of 0.00 D generates spherical power values of 15.5 or 16.0 D OD using different formulas and recommends a toric IOL with 3.75 D cylinder power at the IOL plane. The recommended spherical powers for the left eye range from 9.5 to 11.5 D, and even with implantation of a toric IOL with 6.0 D cylinder, the patient is left with 5 D of residual astigmatism.

A variety of issues necessitates particular attention when patients with keratoconus need cataract surgery. These pertain to the challenges of IOL calculations, correction of astigmatism, long-term biometric stability, and need for concurrent or future management of the keratoconus.

INTRAOCCULAR LENS CONSIDERATIONS

Predictability of IOL power selection in eyes with keratoconus is limited by the difficulty in accurately determining corneal power and obtaining accurate astigmatic axis measurements if a toric IOL is considered. Regardless of the type of IOL chosen, it is important to allow for reversal of contact lens-induced corneal warpage prior to obtaining measurements that will be used for the IOL power calculation.

No established guidelines on the length of time to wait after discontinuation of contact lens wear exist. The interval is longer for RGP contact lenses than for soft contact lenses because RGP contact lenses cause more pronounced corneal changes.¹ Length of RGP lens wear is a predictive factor, but interpatient variability also occurs. Some surgeons recommend waiting 1 week for every year of lens wear. Documenting agreement between consecutive readings performed a few weeks apart will give the surgeon greater confidence that the cornea is stable and the measured values are accurate. In general, clinicians accept a 2-week washout period for soft contact lenses and a 4-week washout period for RGP contact lenses.

Several groups have analyzed their refractive results using various strategies to determine IOL

power in eyes with keratoconus. One small study reported better refractive predictability was achieved using the SRK-II formula than the SRK-T or SRK formulas, but found poorer predictability overall in eyes with moderate or severe keratoconus vs those with only mild disease.²

Another paper reviewing refractive outcomes after cataract surgery in eyes with keratoconus reported good results using actual keratometry (K) values and targeting low myopia in eyes with mild ($n = 35$) or moderate ($n = 40$) keratoconus.³ Use of actual K values with a mean target refraction of -5.4 D in 8 of 17 eyes with severe keratoconus (defined as mean $K > 55$ D) resulted in a large hyperopic biometry prediction error (mean, +6.8 D). For the remaining eyes with severe keratoconus, use of a standard K value of 43.25 D and a mean target refraction of -1.8 D yielded much better results (mean biometry predicted error, +0.6 D).

In a study including 23 eyes, surgeons evaluating outcomes with toric IOL implantation reported the best results were achieved using (1) corneal topography-derived K values and the SRK-T formula in eyes with mild and moderate keratoconus and (2) K values from corneal topography and manual keratometry using the SRK-T and SRK II formulas in those with severe keratoconus.⁴ Although toric IOLs are generally recommended for cylinder reduction in eyes with regular astigmatism, good refractive and functional outcomes were achieved with toric IOL implantation in those patients with stable keratoconus.

Similarly, others have reported favorable results with toric IOL implantation in eyes with stable keratoconus.⁵⁻⁸ Therefore, it appears that a toric IOL might be a reasonable choice if, preoperatively, there is good congruity of the axis using multiple methods of measurement. However, a toric IOL should only be considered to correct astigmatism if the patient will not be using RGP contact lenses postoperatively. In addition, for patients with keratoconus who have been happy wearing RGP contact lenses, and particularly if they would be left with significant astigmatism after toric IOL implantation, a monofocal IOL with an RGP contact lens for astigmatism correction may be the preferred option because it will likely provide the best overall quality of vision.

If it seems probable that the keratoconus will progress to necessitate corneal transplantation, any astigmatic correction rendered at the time of earlier cataract surgery would be irrelevant, an unnecessary expense, and possibly counterproductive because it may contribute to excessive cylinder error postkeratoplasty.

Thus, IOL selection is more complicated in the setting of a younger patient whose keratoconus

may be progressing or in patients with significant corneal scarring because these individuals may become candidates for keratoplasty.

A low-power IOL will be needed in an eye with keratoconus undergoing cataract surgery because of the steepness of the keratoconic cornea. If keratoplasty is performed in the future, the eye will be left with a significant refractive error due to a reduction in the K value after the transplant. When future keratoplasty is a possibility and the patient is willing to continue RGP contact lens wear after cataract surgery, consideration can be given to using the predicted postkeratoplasty K value in IOL power calculations. As a general guide, in eyes with axial myopia, which constitute most patients with keratoconus, keratoplasty with a 0.25-mm donor-to-host diameter disparity will induce an additional 2 to 4 D of myopia.⁹ Use of the same size donor and host trephination significantly flattens the keratometry and induces significantly less myopia than use of disparate donors.¹⁰

KERATOCONUS MANAGEMENT

Corneal cross-linking (CXL) can be performed to stabilize mild-to-moderate keratoconus. When CXL is performed prior to cataract surgery, surgeons should ideally wait at least 6 months for the topography to stabilize before obtaining measurements for IOL power calculation, although stabilization may occur earlier in some patients. Because change in refraction after CXL can continue for years, patients should be counseled that continued contact lens use may be likely even after successful, uncomplicated cataract surgery.

Corneal cross-linking performed after cataract surgery is well tolerated and often induces minimal spherical shift. Once again, however, individual responses are variable, and refraction can continue to change long-term. Considering the potential for CXL to cause a hyperopic shift, which is usually approximately 1 D after 1 year,¹¹ surgeons may wish to target at least 1 to 2 D of myopia in a patient who is anticipated to undergo CXL after cataract surgery.

ALLERGY MANAGEMENT AND OCULAR SURFACE OPTIMIZATION

This case is a reminder that ocular allergies, including allergic conjunctivitis and vernal keratoconjunctivitis, are often associated with keratoconus.^{12,13} Thus, clinicians managing patients with keratoconus should attend to preventive and therapeutic measures for allergy management and ocular surface optimization prior to any surgical planning. In a patient with keratoconus, optimizing the condition of the ocular surface may also be important for enabling successful RGP contact lens wear postoperatively.

The patient in this case presents with several issues that can be affecting the condition of his ocular surface, including long-term contact lens wear, use of medications that can cause ocular dryness (an oral antihistamine and an oral diuretic),¹⁴ and allergic conjunctivitis.

When there is concern about the effects of any systemic medication on dry eye, the ophthalmologist should speak to the prescribing physician about finding an alternative treatment or safe dosage reduction.

Oral antihistamines used to treat an allergy are well-substantiated risk factors for dry eye.¹⁵ Options for managing significant allergic rhinitis that do not cause ocular dryness include an intranasal corticosteroid, an intranasal antihistamine, and the oral leukotriene receptor antagonist montelukast. Although intranasal corticosteroids are generally considered to have a better ocular safety profile than ophthalmic or systemic corticosteroids, they have been associated with the development of a PSC.^{16,17} As the bottom line, however, any corticosteroid used in or around the eye may have ocular side effects, so ophthalmologists need to carefully monitor all patients being treated with these medications.

Allergen avoidance, when possible, is one of the most effective interventions for controlling allergic disease. Allergy testing can now be performed in the ophthalmologist's office with a US Food and Drug Administration–approved skin test for 60 common allergens, and patients often appreciate the convenience of this testing.^{18,19}

SURGICAL DECISION

This patient urgently needed to have cataract surgery to continue functioning in his daily activities and drive safely at night. Thus, it was decided that performing CXL for the keratoconus in his right eye would not meet his needs.

The patient was offered cataract surgery with a toric IOL for the more symptomatic dominant right eye. A toric IOL was deemed acceptable in the context of his having reliably reproduced keratometric axis measurements from 4 different devices and a normal healthy endothelium with minimal corneal scarring.

First, however, the patient was treated to rehabilitate his ocular surface. He underwent allergy skin testing and, on the basis of the findings, practiced allergen avoidance, which, together with use of topical antiallergy medications, resulted in an improvement of his allergy signs and symptoms. He was able to discontinue the oral antihistamine.

Furthermore, his dry eye improved with modification of his oral antihypertensive medication and an aggressive dry eye management regimen that included topical loteprednol, punctal plugs, and an oral nutritional supplement containing omega fatty acids, antioxidants, and other nutrients. His tear osmolarity decreased to 300 mOsm/L OD and 299 mOsm/L OS. His topographic parameters after ocular surface rehabilitation did not change.

One week after undergoing uneventful phacoemulsification with implantation of a 15.5 D single piece hydrophobic acrylic aspheric IOL with 2.57 D cylinder power at the corneal plane (3.75 D cylinder power at the IOL plane) at 121°, the patient was pleased to see 20/25-2 uncorrected OD. With his improved vision, the patient was able to function without his RGP contact lens OD whenever convenience dictated and binocularity was not required. Most of the time, however, he continued wearing his RGP contact lenses OU because they provided better overall binocular vision. The patient eventually underwent successful monofocal IOL implantation OS with a target of -2.0 D myopia.

For more information on ocular surface management, see *A Patient With Mixed Aqueous Deficiency/Evaporative Dry Eye Disease* at http://mededocus.com/downloads/Eye_on_Cataract_Monograph.pdf.

SUMMARY

Cataract surgery will eventually be required in some eyes with keratoconus, and the presence of PSCs at a relatively young age in this patient and other patients with keratoconus may be associated with the use of corticosteroid medications to control allergic disease.

The decision of whether to perform cataract surgery alone or combined with CXL or keratoplasty will need to be individualized, taking into account the keratoconus stage and topographic stability, along with the patient's goals and preferences. Cataract surgeons must recognize the complexities of IOL power selection in eyes with keratoconus, along with the benefits and limitations of correcting astigmatism with a toric IOL, and discuss these issues with patients for shared decision making. As in all patients undergoing cataract surgery, optimization of the ocular surface prior to obtaining preoperative biometry is mandatory for maximizing the refractive outcome and patient satisfaction. Control of the ocular surface disease and allergy should be initiated prior to biometry and throughout the perioperative period, and then with adequate maintenance doses indefinitely thereafter.

REFERENCES

1. Tsai PS, Dowidar A, Naseri A, McLeod SD. Predicting time to refractive stability after discontinuation of rigid contact lens wear before refractive surgery. *J Cataract Refract Surg.* 2004;30(11):2290-2294.
2. Thebpatiphat N, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Cataract surgery in keratoconus. *Eye Contact Lens.* 2007;33(5):244-246.
3. Watson MP, Anand S, Bhogal M, et al. Cataract surgery outcome in eyes with keratoconus. *Br J Ophthalmol.* 2014;98(3):361-364.
4. Hashemi H, Heidarian S, Seyedian MA, Yekta A, Khabazkhoob M. Evaluation of the results of using toric IOL in the cataract surgery of keratoconus patients. *Eye Contact Lens.* 2015;41(6):354-358.
5. Alió JL, Peña-García P, Abdulla Guliyeva F, Soria FA, Zein G, Abu-Mustafa SK. MICS with toric intraocular lenses in keratoconus: outcomes and predictability analysis of postoperative refraction. *Br J Ophthalmol.* 2014;98(3):365-370.
6. Navas A, Suárez R. One-year follow-up of toric intraocular lens implantation in forme fruste keratoconus. *J Cataract Refract Surg.* 2009;35(11):2024-2027.
7. Nanavaty MA, Lake DB, Daya SM. Outcomes of pseudophakic toric intraocular lens implantation in keratoconic eyes with cataract. *J Refract Surg.* 2012;28(12):884-889.
8. Parikakis EA, Chatziralli IP, Peponis VG, David G, Chalkiadakis S, Mitropoulos PG. Toric intraocular lens implantation for correction of astigmatism in cataract patients with corneal ectasia. *Case Rep Ophthalmol.* 2013;4(3):219-228.
9. Doyle SJ, Harper C, Marcyniuk B, Ridgway AE. Prediction of refractive outcome in penetrating keratoplasty for keratoconus. *Cornea.* 1996;15(5):441-445.
10. Wilson SE, Bourne WM. Effect of recipient-donor trephine size disparity on refractive error in keratoconus. *Ophthalmology.* 1989;96(3):299-305.
11. Vinciguerra P, Albè E, Traza S, Seiler T, Epstein D. Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus. *Arch Ophthalmol.* 2009;127(10):1258-1265.
12. Merdler I, Hassidim A, Sorkin N, Shapira S, Gronovich Y, Korach Z. Keratoconus and allergic diseases among Israeli adolescents between 2005 and 2013. *Cornea.* 2015;34(5):525-529.
13. Sharma N, Rao K, Maharana PK, Vajpayee RB. Ocular allergy and keratoconus. *Indian J Ophthalmol.* 2013;61(8):407-409.
14. Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. *J Ophthalmol.* 2012;2012:285851.
15. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). *Ocul Surf.* 2007;5(2):93-107.
16. Fraunfelder FT, Meyer SM. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. *Am J Ophthalmol.* 1990;109(4):489-490.
17. Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use. *J Cataract Refract Surg.* 2011;37(8):1555-1558.
18. Point-of-care testing pays off. *Ophthalmol Manage.* 2014;18:3-11. <http://www.ophthalmologymanagement.com/articleviewer.aspx?articleID=110668>. Published April 1, 2014. Accessed March 23, 2016.
19. Point-of-care testing for ocular allergies. *Ophthalmol Manage.* 2014;18:3-11. <http://www.ophthalmologymanagement.com/articleviewer.aspx?articleID=111695>. Published September 1, 2014. Accessed March 23, 2016.

